Endo has got us by the ballsWith the exclusive right for data release and further testing, Endo can put a choke-hold on Urocidin until they can buy out the Urocidin platform cheap.
1. As long as they do not release the data and do not move speedily forward with further testing, Urocidin remains a non-entity as a cancer drug. No market value.
2. Without the income generated by Urocidin, BNC can foolishly engage in all these manufacturing plants without sales and deplete the money raised, thus weakening our bargaining position again.
3. With the global right to market Urocidin, there is no reason other drug company would entertain the idea of buying out Urocidin. Of course unless they are willing to engage in a long drawn out lawsuit with Endo or pay Endo handsomely to repurchase back the global right.
4. If one were to buy out the MCC platform, we have to first show the efficacy of this platform in other cancers. We don't have the money to do those tests. And at this point, by the departure of François Charette, BNC is showing it has little interest in doing any further test of the MCC platform on other human applications.
So the way I see it, Endo has all the control and effectively block out any competitors in bidding for Urocidin/MCC. It can starve us until we can't hold on, then offer a minimal price to buy-out the Urocidin or even the whole MCC platform. That $500 mil or even less could be what they will use to steal this mega blockbuster.
I truly hope BNC has a very tight non-performance clause in the contract with Endo so they can void this contract within a certain reasonable timeframe if Endo starts playing games.